1.13
-0.03(-2.59%)
Currency In USD
| Previous Close | 1.16 |
| Open | 1.16 |
| Day High | 1.21 |
| Day Low | 1.12 |
| 52-Week High | 4.01 |
| 52-Week Low | 0.36 |
| Volume | 2.29M |
| Average Volume | 3.04M |
| Market Cap | 184.16M |
| PE | -1.2 |
| EPS | -0.94 |
| Moving Average 50 Days | 0.76 |
| Moving Average 200 Days | 1.1 |
| Change | -0.03 |
If you invested $1000 in Tenaya Therapeutics, Inc. (TNYA) since IPO date, it would be worth $73.62 as of August 24, 2025 at a share price of $1.13. Whereas If you bought $1000 worth of Tenaya Therapeutics, Inc. (TNYA) shares 3 years ago, it would be worth $238.9 as of August 24, 2025 at a share price of $1.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire Inc.
Aug 08, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlyi
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed
GlobeNewswire Inc.
Jul 30, 2025 12:30 PM GMT
Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected in Fourth Quarter of 2025 First Patient Dosed in
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
GlobeNewswire Inc.
May 13, 2025 12:30 PM GMT
Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart DiseaseSOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company